Search filters
Filters
Clear All

Phase

  • 10
  • 10
  • 10
  • 10

Found 10 cc-cancer-center trials

A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 01523: A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treat

99 years and younger
All genders
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic …
Learn More

UPCC 02424: A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non- Hodgkin Lymphoma

99 years and younger
All genders
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: can a safe dose of JNJ-90009530 be determined that is safe and well tolerated by patients. will JNJ-90009530 help patients achieve a response and …
Learn More

UPCC 14224: A Single-Arm, Multicenter Phase 2 Study of Neoadjuvant Pembrolizumab with Trastuzumab and Chemotherapy in Resectable HER2+ Esophagogastric Tumors

99 years and younger
All genders
Please refer to Protocol Section 2.0 (Objectives and Scientific Aims). Please refer to Protocol Section 14.0 (Biostatistics). Please refer to Protocol Section 14.0 (Biostatistics).
Learn More

UPCC MM1OA-EA02: A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial

99 years and younger
All genders
To compare the achievement rate of MRDneg CR of either triplet regimen to azacitidine and venetoclax alone within 4 cycles of therapy.
Learn More

UPCC 43424: A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitini

99 years and younger
All genders
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.
Learn More

UPCC 26124 A Phase 2 Study of Alisertib in Combination with Endocrine Therapy in Patients with HR+, HER2-Negative Recurrent or Metastatic Breast Cancer

99 years and younger
All genders
This is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended …
Learn More

UPCC 31824: A LOng-term Follow-up Master Protocol for Participants who Received Cell or Gene Therapies in Other AstraZeneca StUdieS (LOCUS)

99 years and younger
All genders
This study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment. We would like to rely on WCG as the IRB of record for this study.
Learn More

UPCC 06024 A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia (BMT-CTN 2207)

99 years and younger
All genders
This study is a prospective, multicenter Phase II study with participants receiving haploidentical transplantation or unrelated donor transplantation for previously untreated severe aplastic anemia (SAA).
Learn More

NRG-LU007: RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial

99 years and younger
All genders
This trial will be testing if adding radiation to the immunotherapy drug atezolizumab for patients with extensive stage small cell lung cancer (ES-SCLC) can improve progression-free survival (phase II) and overall survival (phase III) when compared to atezolizumab alone. We would like to rely on CIRB as the IRB of …
Learn More

MM1YA-S01: A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Pat

99 years and younger
All genders
This study is being done to compare different experimental drug regimens to the usual treatment (cytarabine and daunorubicin) for acute myeloid leukemia (AML) to find out which options have the best outcomes. We would like to rely on CIRB as the IRB or record.
Learn More